Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN Amgen Inc. daily Stock Chart
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E16.93 EPS (ttm)9.77 Insider Own0.20% Shs Outstand748.36M Perf Week-5.79%
Market Cap123.82B Forward P/E13.26 EPS next Y12.48 Insider Trans-2.37% Shs Float747.47M Perf Month-3.11%
Income7.43B PEG2.14 EPS next Q2.80 Inst Own81.20% Short Float1.07% Perf Quarter9.37%
Sales22.47B P/S5.51 EPS this Y35.20% Inst Trans-0.53% Short Ratio2.82 Perf Half Y8.66%
Book/sh40.12 P/B4.12 EPS next Y9.83% ROA10.10% Target Price190.56 Perf Year22.56%
Cash/sh46.81 P/C3.53 EPS next 5Y7.93% ROE25.90% 52W Range128.27 - 176.85 Perf YTD3.91%
Dividend4.00 P/FCF20.68 EPS past 5Y13.60% ROI12.50% 52W High-6.45% Beta0.94
Dividend %2.42% Quick Ratio3.70 Sales past 5Y7.60% Gross Margin81.40% 52W Low28.99% ATR2.96
Employees17900 Current Ratio4.00 Sales Q/Q5.90% Oper. Margin40.70% RSI (14)35.90 Volatility1.72% 1.61%
OptionableYes Debt/Eq1.10 EPS Q/Q14.90% Profit Margin33.10% Rel Volume1.34 Prev Close169.71
ShortableYes LT Debt/Eq0.93 EarningsOct 27 AMC Payout36.30% Avg Volume2.84M Price165.45
Recom2.40 SMA20-3.53% SMA50-3.32% SMA2005.68% Volume3,794,630 Change-2.51%
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Sep-29-16 05:39PM  Amgens Backup Plan for Kyprolis (AMGN) at Investopedia
05:16PM  [$$] Zymeworks Gains Immuno-Oncology Drugs Through Daiichi Sankyo Deal at The Wall Street Journal
05:06PM  Long Wait for Biosimilar Amjevita (AMGN) at Investopedia
04:40PM  Stocks skid as drugmakers fall, then bank woes deepen losses
04:29PM  Amgen Maintains Migraine Drug Lead (AMGN) at Investopedia
04:09PM  Amgen Migraine Drug Likely To Beat Eli Lilly, Alder, Teva To Market
03:48PM  Amgen Arrowhead Announce Two Cardiovascular Collaborations (AMGN, ARWR) at Investopedia
02:00PM  Arrowhead (ARWR): Collaborations with Amgen for Two Cardiovascular Programs
11:45AM  Arrowhead Pharmaceuticals (ARWR) Stock Surges on Amgen Cardiovascular Drug Partnerships
11:16AM  CORRECTED: mgen and Arrowhead Pharma agree 2 cardiovascular collaborations at MarketWatch
10:58AM  Why Arrowhead Pharmaceuticals Stock Spiked Today at Motley Fool
10:03AM  7 Healthcare Stocks in Focus on World Heart Day
09:56AM  Amgen, Arrowhead team up on gene-therapies for heart disease
08:32AM  Amgen, Inc. breached its 50 day moving average in a Bearish Manner : AMGN-US : September 29, 2016
07:36AM  Amgen and Arrowhead to develop gene-therapies for heart disease
07:30AM  Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations PR Newswire
Sep-28-16 05:50PM  Amgen Reports Positive Results for Trial (AMGN) at Investopedia
04:30PM  Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study PR Newswire
12:25PM  Four Stellar Stocks to Beat the Biotech Slump at TheStreet
10:02AM  Amgen's Kyprolis Fails To Met Endpoint, But It's Not All Bad News
08:51AM  Biotech Stock Roundup: Amgen's Kyprolis Disappoints, Array Up on Cancer Data
07:10AM  Amgen's Multiple Myeloma Drug Kyprolis Fails in Phase III
Sep-27-16 08:32PM  Amgen's Biosimilar Gets FDA Approval (AMGN, ABBV) at Investopedia
07:10PM  Third Value Fund Avenue Buys 3 Stocks in 3rd Quarter
05:13PM  Amgen's Osteoporosis Drug Crosses a Hurdle (AMGN) at Investopedia
04:26PM  Here's Why Ligand Pharmaceuticals Inc Is Plunging Today at Motley Fool
04:23PM  Amgen's Multiple Myeloma Drug Bumbles Key Test Vs. Blockbuster Velcade
04:22PM  Shares of Ligand plunge 12% after Amgen drug misses study goal at CNBC
12:42PM  Why Wells Fargo, Gilead, Newfield, Amgen, and Chesapeake Energy Are Trending at Insider Monkey
12:40PM  Stocks Extend Gains; Facebook Up On Positive Analyst Chatter
11:38AM  Stocks Up After 1st Presidential Debate; Why Tesla Looks Healthiest In Weeks
11:23AM  The Drug Price Increase Debate: Separating The Winners From The Losers
11:15AM  Amgen (AMGN) Stock Slides, RBC: Clarion Trial May Have Failed Due to Design
11:00AM  Amgen's multiple myeloma drug falls short in new-patient study Reuters
10:44AM  Amgen: The Blame Game at Barrons.com
10:12AM  Amgen/UCB's BLA for Osteoporosis Drug Accepted in the U.S.
08:30AM  Amgen Inc Investor Conference Call to discuss CLARION Data scheduled for 8:30 am ET today
08:23AM  Biosimilars in Limelight on FDA Approval of Amgen Drug
07:50AM  Short Sellers Increase Bets in Major Biotechs at 24/7 Wall St.
06:27AM  Amgen Multiple Myeloma Drug Kyprolis Fails to Help Newly Diagnosed Patients
05:13AM  Amgen's multiple myeloma drug falls short in late stage study Reuters
04:00AM  Amgen Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients PR Newswire
Sep-26-16 05:00PM  Amgen Opens Nomination Process For LabCentral Residency PR Newswire
04:03PM  Wall Street Sells Off on Worries Over Clinton-Trump Showdown
04:00PM  Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab PR Newswire
02:38PM  Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies
02:20PM  As Humira Alternative Gets FDA Approval, Is Abbvie in Trouble?
01:53PM  Amgens Venture Funding Initiative (AMGN) at Investopedia
10:05AM  And Then Theres Mylans Specialty Segment, Home of the EpiPen
08:15AM  How Much Will Consumers Save on New Humira Biosimilar? at 24/7 Wall St.
08:01AM  3 Trades to Blaze a Trail Higher in Amgen
06:49AM  Amgen's Biosimilar of Abbvie's Humira Gets FDA Approval
Sep-24-16 01:00AM  [$$] Biotech Is Cheaper Than Big Pharma at Barrons.com
Sep-23-16 07:42PM  FDA Approves Amgen's Biosimilar Version of Humira at The Wall Street Journal
06:22PM  FDA approves lower-cost alternative to biotech drug Humira
06:03PM  FDA Approves Amgen's AMJEVITA (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases PR Newswire
05:50PM  U.S. FDA approves Amgen's copy of AbbVie arthritis drug Humira Reuters
05:05PM  Will Amgen (AMGN) Stock Be Helped By FDA Approval of Humira Biosimilar?
04:44PM  U.S. FDA approves Amgen's cheaper copy of arthritis drug Humira
11:38AM  Top 5 profitable Biotech stocks : September 23, 2016
10:04AM  What Are Analysts Recommendations for Gilead Sciences?
06:17AM  [$$] Biotech Is Cheaper Than Big Pharma: What to Buy at Barrons.com
Sep-22-16 07:00PM  Cramer Remix: Outrunning trading algorithms with the clic...
09:56AM  New Setback for Sanofi's Lantus Increases Need for M&A
Sep-21-16 10:47AM  Amgen (AMGN) Repatha Meets Endpoints in Phase III Study
10:05AM  Ionis, GlaxoSmithKline Partner on Abnormal Protein Treatment
Sep-20-16 03:24PM  Romosozumab From Amgen Inc (AMGN) Shows Positive Results In Osteoporosis at Insider Monkey
12:09PM  The 5 Top-Selling Drugs In The World
11:04AM  Teva, Eli Lilly Have Migraine Treatments in Trial Phases
10:05AM  Alder BioPharmaceuticalss Migraine Therapy Shows Promise
09:00AM  Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab) PR Newswire
08:05AM  Entering Migraine Market Wont Be Easy for Novartis, Amgen
Sep-19-16 01:06PM  Amgen-Servier Collaboration Commercializes Chronic Heart Therapy Globally (AMGN) at Investopedia
11:30AM  Amgen Inc Conference Call to Discuss the results from the romosozumab phase 3 postmenopausal osteoporosis study scheduled for 11:30 am ET today
11:07AM  Amgen Products Threatened by Court Losses (AMGN) at Investopedia
10:38AM  Amgen (AMGN) Parsabiv Gets Positive CHMP Opinion in EU
08:25AM  RBC Says These 4 Top Biotechs Could Have Big Upside Potential at 24/7 Wall St.
Sep-18-16 11:00AM  Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis PR Newswire
Sep-17-16 02:06PM  Technical Analysis of Markets 9/16/16
11:41AM  Is This New Market the Biggest Investment Idea of the Decade? at Motley Fool
10:00AM  AMGN: How Amgen's Stock Price Rose 18.55% in 6 Months at Investopedia
Sep-16-16 05:41PM  [$$] Abingworth Seeds Immunotherapy Startup GammaDelta at The Wall Street Journal
03:54PM  Amgen Targeting Biosimilars (AMGN) at Investopedia
12:09PM  Novartis says experimental drug helps chronic migraine sufferers
07:33AM  Amgen Receives Positive CHMP Opinion For Parsabiv (Etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adult Patients With Chronic Kidney Disease On Hemodialysis PR Newswire
06:54AM  Dr. Reddys Expands Strategic Collaboration with Amgen in India Business Wire
Sep-15-16 04:30PM  Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine PR Newswire
Sep-14-16 06:40PM  Third Avenue Fund Comments on Amgen
04:00PM  Amgen To Webcast Investor Call PR Newswire
01:15PM  Third Avenue Value Fund 3rd Quarter Letter
12:29PM  Amgen, Inc. Value Analysis (NASDAQ:AMGN) : September 14, 2016
12:00PM  Amgen (AMGN) Stock Is Wednesday's 'Chart of the Day'
08:17AM  AbbVie's Battle Royale
Sep-13-16 09:57PM  [$$] Takeda earmarks $15bn for US pharma acquisitions at Financial Times
04:00PM  Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference PR Newswire
01:20PM  Big Pharma Spends Millions to Keep Prices High for California Agencies
10:04AM  Biogen Committed to Bolstering Its Strong Product Pipeline
09:30AM  The Zacks Analyst Blog Highlights: Spectrum Pharmaceuticals, Amgen, AbbVie and Vertex Pharmaceuticals
08:04AM  Product Launches Are Part of Biogens Plans to Boost Revenues
08:04AM  Amgen, Inc. breached its 50 day moving average in a Bullish Manner : AMGN-US : September 13, 2016
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its principal products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of high cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc.; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc.; Advaxis, Inc.; and Dr. Reddy's Laboratories Ltd. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorSep 09Option Exercise71.645,000358,20021,171Sep 13 06:21 PM
Such Annette LouiseVP, Finance and CAOAug 02Sale174.593,000523,7587,183Aug 03 08:14 PM
Balachandran MadhavanEVP, OperationsMay 04Sale154.1230,0004,623,62455,996May 05 08:16 PM
BALTIMORE DAVIDDirectorApr 29Sale157.213,312520,68432,350May 03 07:12 PM
BALTIMORE DAVIDDirectorMar 30Option Exercise50.445,000252,20037,350Mar 31 06:01 PM
HERRINGER FRANK CDirectorMar 14Option Exercise50.445,000252,20030,608Mar 16 06:48 PM
COFFMAN VANCE DDirectorMar 09Option Exercise50.445,000252,20043,447Mar 10 06:55 PM
Bradway Robert AChairman, CEO and PresidentMar 02Option Exercise50.4484,0004,236,960447,102Mar 04 06:07 PM
Bradway Robert AChairman, CEO and PresidentMar 02Sale146.4820,0002,929,566383,102Mar 04 06:07 PM